#United States #New York #class action lawsuit #Pomerantz LLP #Regeneron Pharmaceuticals

Overview of the Investigation

On June 11, 2026, Pomerantz LLP announced that it is actively investigating potential claims from investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding allegations of securities fraud. The firm, recognized for its expertise in corporate and securities litigation, is advising affected investors to reach out for further assistance. This inquiry became prominent following a significant drop in Regeneron's stock price due to unfavorable trial results for its melanoma treatment.

Details on Trial Results

The catalyst for this investigation was a press release by Regeneron on May 15, 2026. The announcement detailed that the Phase 3 trial for its new treatment, which combined fianlimab—a LAG-3 inhibitor—with cemiplimab—a PD-1 inhibitor—did not achieve statistical significance for its primary endpoint: an improvement in progression-free survival (PFS) compared to pembrolizumab (another PD-1 inhibitor). This disappointing news was met with a dramatic market reaction, leading to a stock price decline of $68.57 per share, or nearly 10%, bringing the closing price down to $629.68 on May 16, 2026.

Significance of the Investigative Action

Pomerantz LLP has a formidable reputation in the realm of class action lawsuits, particularly involving corporate misconduct and securities violations. Founded by Abraham L. Pomerantz, a pioneer in the class action field, the firm has spent over 85 years advocating for shareholders and seeking to recover losses resulting from breaches of fiduciary duties or other fraudulent behaviors. In light of the recent developments regarding Regeneron, this investigation may serve as a critical step for investors who believe their investments were adversely affected by misleading information or failed disclosures.

Legal Context of Securities Fraud

Securities fraud encompasses a range of illegal activities committed in connection with the purchase or sale of securities. This often includes misleading statements or omissions of material information that investors rely upon when making financial decisions. The potential for class action suits arises when many investors face similar damages due to a company's practices or communications. In Regeneron's case, investors are encouraged to assess whether they may have valid claims stemming from the company's failure to adequately inform them of the risks associated with the clinical trial outcomes.

Next Steps for Affected Investors

Investors who have experienced losses in their Regeneron shares, particularly those purchased before the drop in price following the trial announcement, are strongly urged to get in touch with Pomerantz LLP. Investors can contact Danielle Peyton directly at [email protected] or via phone at 646-581-9980, ext. 7980, for further guidance on how to proceed legally.

Conclusion

Regeneron Pharmaceuticals, known for its innovative therapies targeting serious diseases, is now facing scrutiny as the ramifications of its trial results and subsequent stock performance unfold. As the situation develops, the ongoing investigation by Pomerantz LLP may lead to significant insights and potential resolutions for investors seeking justice for their losses. Shareholders are advised to stay informed and explore their legal options, as this case exemplifies the importance of transparency and accountability in corporate practices.